background
human
parvoviru
infect
gener
display
selflimit
cours
follow
viral
clearanc
although
case
persist
infect
may
occur
case
sever
pulmonari
diseas
follow
primari
infect
immunocompet
immunocompromis
patient
report
object
investig
preval
clinic
impact
parvoviru
lower
respiratori
tract
studi
design
preval
parvoviru
evalu
realtim
pcr
bronchoalveolar
lavag
bal
adult
patient
fullyear
period
relat
demograph
characterist
underli
patholog
immun
statu
admiss
intens
care
unit
mortal
within
day
discharg
diagnosi
result
parvoviru
detect
patient
without
signific
associ
demograph
characterist
immun
statu
transplant
versu
nontranspl
statu
admiss
intens
care
unit
presenc
haematolog
condit
two
lung
transplant
recipi
surveil
specimen
posit
four
remain
five
patient
present
respiratori
insuffici
signific
associ
mortal
found
posit
patient
die
within
day
patient
present
serolog
evid
recent
acut
infect
viremia
conclus
parvoviru
may
detect
low
frequenc
bal
specimen
patient
differ
patholog
background
find
could
due
chronic
infect
viru
persist
lower
respiratori
tract
also
absenc
symptom
unequivoc
attribut
high
rate
mortal
warrant
need
studi
evalu
opportun
consid
parvoviru
diagnost
workup
lower
respiratori
tract
infect
human
parvoviru
worldwid
distribut
singlestrand
dna
viru
usual
infect
rapidli
divid
cell
line
bone
marrow
erythroid
progenitor
cell
person
infect
year
age
popul
seroposit
age
year
infect
common
late
winter
earli
spring
occur
exposur
infect
respiratori
droplet
blood
product
vertic
mother
fetu
person
infect
asymptomat
present
mild
aspecif
coldlik
symptom
clinic
condit
associ
parvoviru
infect
includ
erythema
infectiosum
arthropathi
hydrop
fetali
immunocompet
individu
haematolog
diseas
includ
aplast
crisi
chronic
red
cell
aplasia
idiopath
thrombocytopen
purpura
immunocompromis
patient
link
parvoviru
infect
hypothes
variou
skin
erupt
neurolog
diseas
rheumatolog
diseas
vasculit
myocardit
syndrom
autoimmun
hepat
case
sever
pulmonari
diseas
immunocompet
immunocompromis
patient
report
literatur
howev
knowledg
studi
systemat
investig
presenc
parvoviru
lower
respiratori
tract
specimen
aim
studi
evalu
preval
clinic
impact
parvoviru
bronchoalveolar
lavag
bal
specimen
hospit
adult
patient
consecut
bal
sampl
collect
period
month
virolog
unit
azienda
ospedalierouniversitaria
san
giovanni
battista
turin
obtain
patient
menwomen
mean
age
standard
deviat
year
rang
studi
multipl
bal
procedur
mean
rang
perform
patient
sampl
patient
collect
less
week
apart
exclud
sampl
episod
evalu
independ
bronchoalveolar
lavag
procedur
perform
investig
caus
unexplain
fever
andor
respiratori
symtpom
includ
dyspnea
cough
haemoptysi
andor
new
infiltr
chest
xray
absenc
abovement
condit
cheke
previou
posit
routin
followup
lung
transplant
recipi
month
posttransplant
subsequ
interv
lung
transplant
recipi
histopatholog
evalu
period
acidschiff
masson
trichrom
haematoxylin
eosin
stain
transbronchi
lung
biopsi
routin
perform
bal
procedur
carri
previous
describ
nucleid
acid
extract
perform
use
autom
nuclisen
easymag
platform
system
marci
letoil
franc
accord
manufactur
instruct
realtim
pcr
assay
perform
realtim
pcr
system
appli
biosystem
monza
itali
use
taqman
platform
primer
parvoviru
detect
design
within
gene
access
number
primer
f
primer
r
probe
tamra
use
primer
express
softwar
appli
biosystem
assay
carri
l
volum
contain
l
extract
specimen
plasmid
dilut
master
mix
platinum
qpcr
supermixudg
rox
invitrogen
nm
primer
nm
probe
uracildna
glycosylas
use
elimin
pcr
carri
contamin
previou
pcr
reaction
pcr
cycl
protocol
follow
c
min
initi
denatur
step
c
min
follow
cycl
c
denatur
c
min
anneal
extens
standard
curv
quantif
dna
construct
plot
threshold
cycl
logarithm
serial
dilut
correspond
plasmid
amplif
data
analyz
sequenc
detect
system
softwar
appli
biosystem
specimen
subject
simultan
taqman
pcr
detect
housekeep
gene
human
gapdh
intern
control
previous
describ
result
consid
accept
presenc
gapdh
threshold
cycl
ct
lower
assay
detect
limit
copiesreact
thu
give
base
analyt
procedur
valu
genom
equival
geq
ml
bal
dynam
rang
realtim
pcr
parvoviru
shown
fig
nucleotidenucleotid
blast
search
short
nucleotid
sequenc
perform
nation
centr
biotechnolog
inform
nation
librari
medicin
web
site
avail
http
wwwncbinlmnihgov
confirm
primer
use
amplifi
virus
pathogen
human
confirmatori
test
nest
pcr
amplifi
region
parvoviru
also
perform
previous
describ
serolog
parvoviru
obtain
clinic
chart
avail
serum
sampl
measur
commerci
enzym
immunoassay
novalisa
parvoviru
igm
igg
novatec
immundiagnostica
dietzenbach
germani
descript
statist
raw
data
percentag
mean
median
use
statist
analysi
chi
squar
test
student
ttest
use
appropri
pvalu
consid
statist
signific
overal
parvoviru
detect
specimen
patient
realtim
pcr
assay
confirm
nest
pcr
main
featur
patient
without
parvoviru
bal
sampl
report
tabl
preval
parvoviru
posit
significantli
differ
relat
demograph
characterist
immun
statu
transplant
versu
nontranspl
statu
admiss
intens
care
unit
presenc
haematolog
condit
two
lung
transplant
recipi
posit
surveil
bal
specimen
histopatholog
evalu
disclos
find
suggest
viral
infect
parvoviru
significantli
associ
mortal
within
day
posit
patient
requir
mechan
ventil
respiratori
insuffici
die
within
day
regard
season
specimen
posit
parvoviru
collect
autumn
winter
overal
serolog
parvoviru
avail
patient
includ
six
seven
posit
parvoviru
bal
specimen
evid
past
infect
igg
posit
igm
neg
none
evid
acut
recent
infect
parvoviru
load
rang
geqml
bal
median
significantli
differ
relat
abovement
patient
characterist
main
featur
parvoviru
patient
report
tabl
realtim
pcr
assay
parvoviru
result
neg
avail
six
serum
specimen
patient
posit
bal
sampl
parvoviru
common
caus
infect
worldwid
definit
diagnosi
made
detect
igm
viral
dna
serum
sampl
well
may
detect
respiratori
secret
gener
infect
immunocompet
individu
display
selflimit
cours
follow
clearanc
viru
host
although
case
persist
infect
may
occur
despit
presenc
igg
antibodi
besid
blood
bone
marrow
persist
parvoviru
shown
skin
synovi
tonsil
liver
myocardi
tissu
kidney
although
parvoviru
infect
persist
associ
wide
rang
diseas
find
viral
dna
differ
tissu
specimen
argu
possibl
pathogen
role
clinic
context
suggest
detect
suffici
postul
relationship
viru
specif
diseas
present
studi
investig
presenc
clinic
impact
parvoviru
bal
specimen
report
parvoviru
pneumonia
immunocompromis
immunocompet
patient
result
primari
infect
describ
literatur
studi
investig
presenc
parvoviru
lower
respiratori
tract
specimen
larg
group
hospit
adult
patient
base
result
parvoviru
found
small
percentag
patient
differ
patholog
background
without
evidenc
signific
preval
specif
subgroup
patient
regard
potenti
relationship
particular
clinic
pattern
although
five
seven
posit
patient
present
acut
respiratori
condit
two
lung
transplant
recipi
found
also
surveil
bal
seem
argu
possibl
pathogen
role
parvoviru
viru
could
repres
innoc
bystand
replic
favour
impair
pulmonari
background
chronic
parvoviru
infect
cryptic
site
absenc
viremia
delay
clearanc
area
suggest
cerebrospin
fluid
evidenc
cerebrospin
fluid
routin
taken
part
routin
investig
new
case
leukemia
pathogenesi
hypothes
relat
parvoviru
support
fact
known
caus
enceph
similarli
base
result
like
anoth
cryptic
site
viral
persist
repres
lower
respiratori
tract
moreov
note
viral
load
moderatelow
symptomat
surveil
case
specimen
one
present
least
coinfect
anoth
viru
mainli
herpesvirus
rhinoviru
howev
may
like
also
herpesviru
dna
find
attribut
latenc
lung
previous
describ
hand
presenc
respiratori
insuffici
four
seven
patient
posit
bal
specimen
frequent
associ
mortal
within
day
case
suggest
need
investig
presenc
parvoviru
bal
lung
biopsi
specimen
role
differ
clinic
set
intens
care
unit
conclus
result
suggest
parvoviru
may
detect
low
frequenc
bal
specimen
obtain
hospit
adult
patient
differ
patholog
background
find
could
due
chronic
infect
viru
persist
lower
respiratori
tract
also
absenc
symptom
unequivoc
attribut
nevertheless
high
rate
mortal
posit
case
warrant
need
studi
evalu
opportun
consid
parvoviru
diagnost
workup
lower
respiratori
tract
infect
